article˜The œLancet. Gastroenterology & hepatologyMar 9, 2022Closed access

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

DODo-Youn OhKLKyung-Hun LeeDLDae-Won LeeJYJeesun YoonTKTae-Yong Kim

Seoul National University Hospital · Seoul National University · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

309
total citations
FWCI
65.88
Percentile
100%
References
30
Citations per year

Authors

17
  • DO
    Do-Youn OhCorresponding
  • KL
    Kyung-Hun Lee
  • DL
    Dae-Won Lee

    Seoul National University Hospital

  • JY
    Jeesun Yoon

    Seoul National University Hospital

  • TK
    Tae-Yong Kim

Topics & keywords

Topics
Keywords
  • Durvalumab
  • Tremelimumab
  • Gemcitabine
  • Cisplatin
  • Biliary tract cancer
  • Phases of clinical research
  • Biliary tract
No related works found for this paper.

Funding